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SUMMARY
Weanalyzed the in silicopurifiedDNAmethylation signaturesof 82mantlecell lymphomas (MCL) incomparison
with cell subpopulations spanning the entire B cell lineage. We identified two MCL subgroups, respectively
carrying epigenetic imprints of germinal-center-inexperienced and germinal-center-experienced B cells, and
we found that DNAmethylation profiles during lymphomagenesis are largely influenced by themethylation dy-
namics in normalB cells. An integrative epigenomic approach revealed 10,504differentiallymethylated regions
in regulatory elements marked by H3K27ac in MCL primary cases, including a distant enhancer showing
de novo looping to the MCL oncogene SOX11. Finally, we observed that the magnitude of DNA methylation
changes per case is highly variable and serves as an independent prognostic factor for MCL outcome.
Significance
Recent studies on the DNAmethylome of cancer cells are reshaping our perception on the pathogenic role of this epigenetic
mark, including reports that suggest a major link between the dynamic DNA methylation landscape of normal cell differen-
tiation and neoplastic transformation. Here, we performed a detailed epigenomic analysis of mantle cell lymphoma (MCL), a
heterogeneous B cell tumor, in the context of the DNAmethylome of the entire normal B cell maturation program. Our results
provide insights into the cellular origin, pathogenetic mechanisms, and clinical behavior of MCL, and we highlight that inte-
grative analyses of the DNA methylome, histone modifications and three-dimensional interactions in cancer cells can iden-
tify potential epigenetic drivers at distant regulatory elements of key oncogenes.
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INTRODUCTION
The existence of alterations in the DNA methylome of cancer
cells has been known since the early 1980s (Feinberg and Vo-
gelstein, 1983; Gama-Sosa et al., 1983). Despite the widely
reported role of DNA methylation in cancer (Baylin and Jones,
2011; Esteller, 2008), the analyses of whole DNA methylomes
are now questioning the accepted view of DNA methylation as
a major player in gene deregulation. These analyses are
revealing that the roles of this epigenetic mark are more variable
and context dependent than previously appreciated (Jones,
2012; Kulis et al., 2013) and that a large fraction of the DNA
methylation changes in cancer do not seem to have any
apparent functional effect (Agirre et al., 2015; Keshet et al.,
2006; Ziller et al., 2013). So far, cancer epigenomics studies
have detected tumor-specific changes by comparing tumor cells
with their normal counterparts, or by comparing longitudinal
tumor samples. However, it is becoming increasingly evident
that regions with dynamic DNAmethylation levels in normal cells
seem to be prone to be altered upon neoplastic transformation
(Feinberg, 2014; Hansen et al., 2011; Kulis et al., 2015). Thus,
a detailed analysis of a specific tumor type in the context of
the entire differentiation program of its normal cellular counter-
part will reveal new insights into the role of DNA methylation in
tumorigenesis.
Mantle cell lymphoma (MCL) is a B cell lymphoma that shows a
broad spectrum of clinical behaviors and biological features
(Jares et al., 2012). Despite the heterogeneity, the unifying factor
inMCL is the t(11;14) (q13;q32) translocation leading to cyclin D1
gene (CCND1) deregulation, which is considered to be a primary
driver event in this disease (Jares et al., 2007). Most MCLs have
an aggressive clinical behavior with poor survival rates. How-
ever, some cases classified as leukemic non-nodal MCLs
show a rather indolent clinical course even in the long-term
absence of chemotherapy (Royo et al., 2012). Aggressive cases
are highly proliferative and seem to be associated with a lack or
low levels of somatic mutations in the IGHV locus and de novo
expression of SOX11, which is not expressed in normal B cells.
In contrast, leukemic non-nodal MCLs show a very low prolifer-
ation index, have high levels of somatic mutations in the IGHV
locus, and lack SOX11 expression. However, some of these
SOX11-negative MCLs can acquire oncogenic mutations and
progress toward a fatal clinical outcome (Jares et al., 2012).
The DNA methylome of MCL remains largely unknown, as it
has only been analyzed in promoter regions (Enjuanes et al.,
2013; Halldorsdottir et al., 2012; Leshchenko et al., 2010; Rah-
matpanah et al., 2006). To obtain deeper insights into MCL
epigenetics, we have applied an analytic strategy to deconstruct
the DNAmethylome of MCL in the light of the complete normal B
cell differentiation program (Kulis et al., 2015).
RESULTS
Deconvolution and In Silico Purification of MCL DNA
Methylation Signatures
Wegenerated genome-wide DNAmethylation profiles of 82MCL
samples using the HumanMethylation450 BeadChip (Illumina)
(Bibikova et al., 2011). Biological and clinical information of
the analyzed cases is shown in Table S1. As normal controls,
we used 67 samples from ten different cell subpopulations span-
ning the entire B cell lineage (Kulis et al., 2015). We considered
two potential confounding variables that may affect our epige-
nomic analyses, i.e., the biological origin of the samples (lymph
node versus peripheral blood) and the tumor cell content.
We did not identify any consistent differential methylation
pattern between lymph node and peripheral blood samples
(data not shown). However, despite the generally high tumor
cell content of the selected MCL samples (median, 89%; range,
56%–100%; Table S1), purity affected the DNA methylation an-
alyses (Figure S1). Therefore, we developed a strategy to decon-
volute the DNA methylation signal of mixed subpopulations and
to isolate in silico the DNA methylation levels of the tumor cells
(Figure 1A). To that end, we adapted a published algorithm
(Houseman et al., 2012; Jaffe and Irizarry, 2014) to estimate
the fractions of six different hematopoietic cell types (Reinius
et al., 2012) in our tumor samples (Figure 1B). The normal
B cell fraction in MCL samples is estimated to be very low
(0%–0.3%) (Saba et al., 2016), therefore the total B cell fraction
was taken as a measure for the tumor fraction. Using the
adapted algorithm, we calculated the proportion of each cell
type in our samples. We validated the approach by comparing
the in silico estimated tumor B cell fraction with the sample purity
measured by flow cytometry in 32 MCL samples (Pearson
r = 0.947; Figure 1C). Finally, we used the DNA methylation esti-
mates of the normal non-B cell subtypes together with their
respective proportions to extract the DNA methylation signature
derived from the tumor B cells in each MCL sample (Figure 1D).
These pure DNA methylation estimates of the tumor fraction
were used for all downstream analyses.
Genome-wide DNA Methylation Analysis Reveals Two
Major MCL Subgroups with Distinct Clinicobiological
Features
We performed an unsupervised principal component analysis
(PCA) of DNA methylation data from normal B cell subpopula-
tions andMCL samples (Figure 2A). The two first components or-
dered normal B cells according to their maturation stage, mainly
separating germinal-center-inexperienced B cells (uncommitted
precursors, pre-B cells, and naive B cells) from germinal-cen-
ter-experienced B cells (germinal-center B cells, memory B cells,
and plasma cells). Principal component 1 showed that all MCLs
are globally more similar to germinal-center-experienced B cells
(i.e., antigen experienced). In contrast, principal component 2
split MCLs into two subgroups: cluster 1 (C1) (n = 62) and cluster
2 (C2) (n = 20), which respectively showed a DNA methylation
pattern more similar to germinal-center-inexperienced B cells
and germinal-center-experienced B cells. These subgroups
showed significant clinicobiological differences (p < 0.001) in,
for example, IGHV mutation levels, SOX11 expression, number
of copy number alterations, nodal presentation, and requirement
of treatment at diagnosis (Figure 2B). Furthermore, C1 cases
showed a significantly worse overall survival than C2 cases
(p = 0.026) (Figure S2A).
Next, we compared C1 and C2 MCLs, and identified 13,691
differentially methylated CpGs (Figure 2C). Most CpGs hypome-
thylated in C2 MCLs linked C1 cases to germinal-center-inexpe-
rienced cells and C2 cases to germinal-center-experienced B
cells (Figure 2C), further supporting the concept shown in the
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second component of the PCA analysis (Figure 2A). In contrast,
hypomethylation in C1 was predominantly a de novo event
targeting regions that are highly methylated both in C2 MCLs
and normal B cells (Figure 2C). These regions frequently targeted
CpG island shores and gene bodies (Figure 2D). Furthermore, we
performed chromatin immunoprecipitation sequencing (ChIP-
seq) with six histone marks and generated chromatin states
from sorted naive and memory B cells from healthy donors; we
observed that hypomethylated regions in C1 MCLs were en-
riched for enhancers and transcribed regions (Figure 2E). Naive
andmemory B cells have been previously suggested as potential
cells of origin of IGHV unmutated and mutated MCLs, respec-
tively (Navarro et al., 2012). Therefore, in this study we used
them as normal counterparts of C1 MCLs and C2 MCLs,
respectively. Interestingly, the genes affected by hypomethyla-
tion in C1 MCLs were significantly enriched (adjusted p < 0.05)
in several pathways (Table S2), such as NOTCH signaling (Fig-
ure S2B), which has been previously linked toMCL pathogenesis
of the IGHV unmutated/SOX11-positive subgroup (i.e., C1) (Bea
et al., 2013; Kridel et al., 2012).
Comparing MCL Groups with Their Normal Cell
Counterparts Reveals a Major Epigenetic Link with
Normal B Cell Differentiation
Next, we sought to detect epigenetic differences in theMCL sub-
groups compared with their respective putative normal counter-
parts. We observed 60,622 differentially methylated CpGs in C1
MCLs (78% hypomethylated) in comparison with naive B cells
and 5,469 CpGs in C2 MCLs (84% hypomethylated) in compar-
ison with memory B cells (Figure 3A). Interestingly, we found
Figure 1. Deconvolution of DNA Methylation Data and In Silico Purification of MCL Methylation Estimates
(A) Work flow of the deconvolution process in MCL samples.
(B) Estimation of the proportion of hematopoietic cell subpopulations in MCL samples and in sorted B cells, CD8+ T cells, CD4+ T cells, natural killer (NK) cells,
monocytes, and granulocytes. Sorted cell subpopulations (right part of the heatmap) are correctly predicted and MCLs show a gradient from lower to higher
proportion of B cells (left part of the heatmap).
(C) The proportion of B cells in MCL samples as detected by flow cytometry and by the in silico prediction are highly correlated.
(D) Heatmaps of the CpGs representative of each cell type (n = 580) showing the initial methylation estimates from the MCL samples (left), the extraction of
the DNA methylation signature from contaminating non-B cells (middle), and the final in silico purification of the DNA methylation estimates from MCL cells
(right).
See also Figure S1 and Table S1.
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that 61%–79% of these CpGs overlapped with those previously
described to show variable DNA methylation levels during
normal B cell differentiation (Kulis et al., 2015) (Figures 3B and
3C). This finding suggests that only a fraction of the DNAmethyl-
ation changes in MCLs compared with their normal counter-
parts is unrelated to normal B cell differentiation and thus,
strictly tumor specific. Those CpGs dynamically methylated
both in MCL and B cell differentiation (from now on called
B cell-related CpGs) and those exclusively changing in MCL
(from now on called B cell-independent CpGs) were in part en-
riched in different chromatin states defined in naive and memory
B cells (Figure 3D). Overall, hypomethylation in MCL in both
the B cell-related and independent fractions was enriched for
enhancer elements. On the contrary, B cell-related hypermethy-
lated CpGs in MCL were located both in H3K27me3-repressed
and poised promoters, whereas those in the B cell-independent
fraction were mostly associated with poised promoters (Fig-
ure 3D). To identify chromatin state transitions in relationship
with DNA methylation changes, we generated ChIP-seq profiles
and chromatin states from two MCL cases representative for C1
Figure 2. Identification of Two MCL Subgroups Based on DNA Methylation Profiling
(A) Unsupervised PCA of 82 MCLs and 67 normal B cell subpopulations using the adjusted methylation values of all CpGs analyzed with the 450K array. The two
main principal components are shown together in a two-dimensional plot and separately. Vertical and horizontal dotted lines point to the cut-off value separating
germinal-center-inexperienced and -experienced B cells. Normal B cells are surrounded by a dotted gray line.
(B) Comparison of biological and clinical features between the two epigenetic subgroups (i.e., C1 and C2). The presence of oncogenic mutations is defined as
having a mutation in at least one of the following genes: BIRC3, MEF2B, NOTCH2, TLR2, TP53, and WHSC1. Data show means ± SD. ***p < 0.001; n.s., not
significant (Fisher’s exact test or t test for independent samples).
(C) Heatmap of the CpGs differentially methylated in C1 compared with C2.
(D) Location of the hypo- and hypermethylated CpGs between C1 and C2 MCLs in the context of CpG islands (CGI) and gene-related regions.
(E) Chromatin states of naive (upper panel) andmemory (lower panel) B cells of the differentially methylated CpGs between C1 and C2MCLs. The numbers inside
each cell point to the percentage of CpGs belonging to a particular chromatin state. The differentially methylated CpGs annotated in (D) and (E) are the same as
those shown in (C). Backg, background; bm-PCs, plasma cells from bone marrow; C1 MCLs, germinal-center-inexperienced MCLs; C2 MCLs, germinal-center-
experienced MCLs; gcBCs, germinal-center B cells; HPCs, hematopoietic progenitor cells; Hyper, hypermethylation; Hypo, hypomethylation; iBCs, immature
B cells; memBCs,memory B cells fromperipheral blood; naiBCs, naive B cells fromperipheral blood; preB1Cs, pre-BI cells; preB2Cs, pre-BII cells; t-PCs, plasma
cells from tonsil; TSS, transcriptional start site; UTR, untranslated region.
See also Figure S2 and Table S2.
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Figure 3. DNA Methylation of MCL Subgroups versus Their Respective Normal B Cell Counterpart
(A) Number of differentially methylated CpGs between C1 and naiBCs, and between C2 and memBCs.
(B) Percentage of B cell-related and B cell-independent CpGs differentially methylated in each comparison.
(legend continued on next page)
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and C2, and compared them with those from naive and memory
B cells, respectively (Figures 3E, S3A, and S3B). Overall, 56% of
the regions did not seem to change their chromatin state in MCL
upon DNA methylation alteration. However, we observed that
repressed regions losing DNA methylation tend to change to-
ward chromatin states related to activating histonemodifications
(especially H3K4me3 in poised promoters andH3K4me1 inweak
enhancers) (Figure 3E); this phenomenon is more prominent in
the B cell-independent fraction than in the B cell-related fraction
in C1 (52% versus 18%, p < 0.001). In the case of hypermethy-
lated regions in C1 MCLs, we observed that active and weak
promoters in naive B cells turn into poised promoters in MCL
and that poised promoters turn into H3K27me3-repressed re-
gions (Figure S3A).
Individual Epigenetic Heterogeneity in MCL
The data presented in Figures 2 and 3 suggest that both MCL
groups are epigenetically heterogeneous. Based on these ob-
servations, we have applied a second analytic strategy to tackle
individual epigenetic variation of MCL cases in the context of the
entire B cell maturation program. We compared the DNA meth-
ylome of each individual MCL case with the hematopoietic pro-
genitor cells (HPCs) (using as cut-off an absolute difference of
methylation values of at least 0.25). This seemingly unorthodox
approach has the advantage that it uses a fixed reference point
for B cell neoplasms with different normal counterparts, and al-
lows us not only to precisely dissect but also to compare the
DNA methylation modulation of each individual MCL sample
from the moment of B cell commitment up to and beyond its
cell of origin. We observed that the total number of changes
per case is highly variable both in C1 and C2 MCLs (ranging
from 62,888 to 143,925 CpGs) (Figure 4A). Furthermore, we iden-
tified that the DNA methylation levels of the MCLs correlate less
among each other than within normal B cells, showing that the
inter-sample heterogeneity is much higher in MCLs than in
normal B cells (Figure 4B). In addition, we saw that 318,659
unique CpGs (98% of the 106,552 B cell-related and 53% of
the 368,442 B cell-independent CpGs measured by the 450K
array) showed a DNA methylation change compared with
HPCs in at least one MCL case, suggesting that a large frac-
tion of the human methylome can be modulated in normal and
neoplastic B cells.
Next, to identify regions that may play a role in MCL develop-
ment, we sought to identify B cell-independent CpGs with recur-
rent differential methylation in C1 and C2 MCLs. We detected
that the majority of the differentially methylated sites between
MCL and HPC were present in one or few MCLs, and that highly
recurrent changeswere rare events (Figure 4C). Furthermore, the
relative proportion of differentially methylated regionsmarked by
particular chromatin states (as defined in primary MCL cases),
such as heterochromatin and enhancers, was related to the level
of recurrence of the DNAmethylation changes (Figures 4D, S4A,
and S4B). These findings suggest that most B cell-indepen-
dent changes in individual MCLs seem to target non-functional
regions (i.e., heterochromatin) while commonly altered CpGs,
although rare, target regulatory elements (i.e., enhancers).
An additional interesting aspect of this analysis of individual
variation was that the number of B cell-related and B cell-
independent differentially methylated CpGs per MCL case
were linearly related (Pearson r = 0.82 and 0.91 for C1 and C2
MCLs, respectively; p < 0.001) (Figure 4E). This association sug-
gests that the mechanisms underlying differentially methyla-
tion in B cell-related and B cell-independent CpGs are shared,
even though different cases showdifferent degrees of epigenetic
changes. In addition, in C1 MCLs, we detected 6,245 CpGs with
an inverse correlation between their DNA methylation levels and
the percentage of IGHV somatic hypermutation (SHM) (Figures
S4C–S4F), a phenomenon not observed in C2 cases. The fact
that some C1 MCLs concurrently show some degree of SHM
and DNA demethylation suggests that C1 MCLs may be derived
from germinal-center-inexperienced B cells at different matura-
tion stages, ranging from those lacking SHM to those showing
low but variable degrees of SHM, which correlate with epigenetic
changes (Kolar et al., 2007; Sims et al., 2005).
Deep Characterization of the MCL Methylome
by Whole-Genome Bisulfite Sequencing
We sequenced the entire DNA methylome of two highly pure
(95% and 99% tumor cells) representative MCLs previously
analyzed by 450K microarrays (one from MCL C1 and one from
MCL C2; Figures S5A–S5C) at a single base pair resolution
(483 mean coverage; Table S3), and we analyzed them in the
context of the DNA methylome of the B cell lineage (Kulis et al.,
2015) (Figures 5A, S5D, and S5E). The methylation estimates
obtained by the two methods were highly comparable (Pearson
r = 0.97 for both cases; Figure S5C). We compared each MCL
with HPCs as fixed reference, and we defined both differentially
methylated CpGs (DMCs) and differentially methylated regions
(DMRs). DeterminingDMRs increased the detection of regulatory
regions compared with detecting DMCs, and therefore we
continued our analyses using the DMR strategy (Figures S5F–
S5I). Subsequently, we split the CpGs within DMRs into B cell-
related and B cell-independent CpGs, and we observed that
55%–92% overlapped with those modulated during normal
B cell differentiation (Figure 5B). Intriguingly, most DMRs in
MCL either contained only B cell-related or a mixture of both B
cell-related and B cell-independent CpGs, and few were exclu-
sively B cell independent (Figures 5C–5E). More specifically, in
the C1 MCL case, only 9.3% of the hypomethylated and 5.6%
of the hypermethylated DMRs were B cell-independent, and
these numbers dropped to 1% and 1.2%, respectively, in the
C2 MCL case (Figure 5D). This analysis suggests that those
(C) Heatmaps of differentially methylated CpGs in C1 MCLs compared with naiBCs (left) and in C2 MCLs compared with memBCs (right) in the context of normal
B cell differentiation.
(D) Chromatin states in naiBCs and memBCs of the differentially methylated CpGs between C1 and naiBCs (left panel), and between C2 and memBCs (right
panel), respectively. The numbers inside each cell point to the percentage of CpGs belonging to a particular chromatin state.
(E) Transition of the chromatin states from naiBCs to a C1MCL case in the B cell-related and B cell-independent hypomethylated CpGs. The numbers inside each
cell point to the total number of CpGs in each transition.
See also Figure S3.
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regions prone to acquire differential methylation during normal B
cell differentiation seem to be predisposed to be further altered in
the context of malignant transformation, and that regions with
pure tumor-specific DMRs seem to be a rare phenomenon.
Identification of Potential Epigenetic Drivers inMCL and
Detection of Distant SOX11 Enhancers
Next, we aimed to study whether DMRs between C1 and C2
MCLs can lead to the detection of potential functional regulatory
regions that are differentially active in these two groups. By
comparing them, we detected 26,603 DMRs hypomethylated
in C1 and 4,457 DMRs hypomethylated in C2. Approximately
60% of these DMRs contained a mixed pattern of B cell-related
and B cell-independent CpGs (Figure 6A). Subsequently, we
generated ChIP-seq profiles of the same MCL cases studied
by whole-genome bisulfite sequencing (WGBS) and overlapped
the detected DMRs with the genomic regions simultaneously
containing H3K27ac, which marks active regulatory elements
(Heintzman et al., 2009). We observed that hypomethylated
DMRs in the C1 MCL case had a substantial overlap (39%)
with H3K27ac peaks, which were predominantly present either
in the MCL C1 case only or in both MCL cases (Figures 6B and
6C, and Table S4).
We then analyzed the chromatin architecture of the DMRs
within H3K27ac peaks in further detail by taking into account
H3K4me1, mostly marking enhancers, and H3K4me3, marking
promoters (Figures 6D–6F). The hypomethylated DMRs in the
C2 MCL case that are located within H3K27ac peaks (n = 118,
Figure 4. Association between B Cell-Related and B Cell-Independent DNA Methylation Changes in MCL
(A) Number of differentially methylated CpGs for each individual normal B cell subpopulation and MCL compared with HPCs.
(B) Correlation coefficient among samples of the different groups.
(C) Number of B cell-related and B cell-independent differentially methylated CpGs based on their level of recurrence in C1 (1st and 3rd panel) and C2 (2nd and 4th
panel).
(D) Chromatin states, defined in an MCL primary case representative of C1 cases, of the hypomethylated CpGs between C1 and naiBCs divided into quartiles
based on their level of recurrence. Q1, recurrent in 0%–25% of patients; Q2, recurrent in 25%–50% of patients; Q3, recurrent in 50%–75% of patients; Q4,
recurrent in 75%–100% of patients.
(E) Scatterplot showing the number of B cell-related (x axis) and B cell-independent (y axis) CpGs differentially methylated in individual MCLs and normal B cells
compared with HPCs.
See also Figure S4.
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2.6%) in the corresponding MCL case but not in the C1 MCL
case, normal naive or memory B cells, showed simultaneous
presence of H3K4me1 and H3K4me3 (Figure 6D), suggesting
that these regions represent de novo active promoters.
The hypomethylated DMRs (n = 4,452, 16.7%) in the C1 MCL
case within H3K27ac peaks only in the corresponding MCL
case and not in MCL C2, normal naive or memory B cells,
showed enrichment for H3K4me1 (Figure 6E), pointing toward
de novo activation of enhancers at these regions. Furthermore,
the DMRs within H3K27ac peaks appeared to be significantly
enriched (p < 0.001) in mixed and B cell-independent DMRs
(Figures 6D–6F). Similar results were obtained analyzing the
overlap between DMRs and super enhancers (Figure S6 and
Table S5). Overall, these results show that DMRs between C1
and C2 MCLs may point toward differential active enhancers
and promoters in these samples, especially when they contain
Figure 5. Analysis of the MCL Methylome by WGBS
(A) Circular representation of the DNAmethylation levels for HPC, preB2C, naiBC, gcBC,memBC, and bm-PC, as well as twoMCLs representative for C1 andC2,
respectively. CpG methylation levels are averaged over 10 Mb genomic windows.
(B) Percentage of B cell-related and B cell-independent CpGs differentially methylated in C1 MCL and C2 MCL versus HPC.
(C) Graphical representation of the different DMR types: DMRs with only B cell-related CpGs are defined as B cell-related DMRs (left), DMRs containing both
B cell-related and B cell-independent CpGs are defined as mixed DMRs (middle), and DMRs with only B cell-independent CpGs are defined as B cell-inde-
pendent DMRs (right). Filled and empty circles represent methylated and unmethylated CpGs, respectively.
(D) Number of B cell-related, mixed, and B cell-independent DMRs between C1 versus HPC and between C2 versus HPC.
(E) Distribution of DNA methylation levels for the different DMRs types defined between C1 MCL and HPC and between C2MCL and HPC. Boxplots show upper
and lower quartiles and the median, and whiskers represent minimum and maximum, with outer points indicating outliers.
See also Figure S5 and Table S3.
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Figure 6. Integrative Analysis of Differentially Methylated Regions and Histone Modifications
(A) Distribution of DMRs defined by WGBS between the MCL cases representative of C1 (SOX11-positive) and C2 (SOX11-negative) into three different DMR
types (B cell-dependent, B cell-independent, or mixed DMRs; NA, non-assigned).
(B) Number of DMRs between the C1 and C2 MCL cases and their overlap with H3K27ac peaks in these MCL cases.
(C) Distribution of the DMRs showing an overlap with H3K27ac peaks in the C1 MCL case only, the C2 MCL case only or in both cases. The background rep-
resents all H3K27ac peaks in the C1 and C2 MCL case, and shows which percentage is unique for these cases (yellow and dark brown) and which percentage
overlaps (light brown). ***p < 0.001 (Fisher’s test).
(D–F) Heatmaps showing the read density of H3K27ac, H3K4me1, and H3K4me3 ChIP-seq in the C1MCL case, C2 MCL case, naive B cells (NBC), and memory
B cells (MBC) at selected DMRs (±10 kb). Only the DMRs showing significant differences versus the background in (C) were used for these heatmaps,
(legend continued on next page)
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CpGs that change only in MCL (i.e., mixed/B cell-independent
DMRs).
One striking example is a cluster of mixed DMRs hypomethy-
lated in the C1 MCL case overlapping with an enhancer region
located 624–653 kb downstream of SOX11 only in the SOX11-
expressing MCL C1 case (Figure 7A). A set of 4C-seq analyses
(Simonis et al., 2007; van de Werken et al., 2012) showed that
this region presents high contact frequencies with the SOX11
gene in three-dimensional (3D) space in the representative C1
primary MCL case and three SOX11-positive MCL cell lines
but not in the C2 MCL case, in the SOX11-negative MCL cell
line JVM-2, or in normal naive and memory B cells (Figures 7A
and 7B). To investigate whether the association between DNA
hypomethylation of this distant enhancer and the expression
of SOX11 is a recurrent phenomenon in MCL primary cases,
we analyzed the DNA methylation status of this region by
bisulfite pyrosequencing in additional primary SOX11-positive
(n = 12) and SOX11-negative MCL cases (n = 10). In this way,
we confirmed that the identified regulatory region is de novo
demethylated in SOX11-positive (average methylation level
14%–21%) compared with SOX11-negative cases (average
methylation level 63%–85%, p < 0.01) or naive B cells (average
methylation level 79%–91%) (Figure 7C and Table S6). However,
whether this demethylation is a cause or a consequence of the
enhancer activation and SOX11 expression remains to be eluci-
dated. These data suggest a model in which aberrant SOX11
expression in MCL is associated with a de novo activation of a
distant enhancer element that interacts with the SOX11 locus
in 3D space (Figure 7D).
Link among Epigenetic Burden, Genetic Changes, and
Clinical Outcome of MCL Patients
In addition to the significant survival difference between C1 and
C2MCLs (Figure S2A), we postulated that the epigenetic burden
(i.e., number of differentially methylated sites regardless of
their relationship to normal B cells) may also be associated
with clinical behavior. Indeed, in both MCL subgroups, we found
that the number of DNA methylation changes compared with
HPCs showed a significant linear association with the clinical
outcome, approximately doubling the risk of death with each
10,000 methylation changes (Figures 8A and S7A). Beyond this
quantitative association, we also calculated the threshold of
DNA methylation changes that maximizes the difference in clin-
ical outcome between two subsets of patients (Figures 8B and
8C as well Figures S7B–S7D). Furthermore, we compared DNA
methylation changes with the presence of mutations using a
set of six recurrent driver genes in MCL (Bea et al., 2013). We
observed that cases with gene mutations in C2 MCLs, but
not C1 MCLs, displayed a significantly higher number of CpG
methylation changes (Figures 8D and 8E). To determine whether
these observations can be linked to cell proliferation, we calcu-
lated the proliferation signature in 25 of our MCL cases (Navarro
et al., 2012). As expected, MCL C1 cases are in general more
proliferative than C2 cases (Figure S7E), but the proliferation
signature was positively correlated with the number of epige-
netic changes only in C2 MCLs (Figure S7F). Finally, we per-
formed a multivariate Cox regression model with six variables
related to MCL prognosis (Supplemental Experimental Proced-
ures) and identified that the number of DNAmethylation changes
was the strongest independent prognostic factor in our MCL
series (p = 1.4 3 105) followed by IGHV identity levels (p =
0.0015) and age (p = 0.0019) (Figure 8F). These data suggest
that patients with more epigenetic changes have a worse clinical
outcome and that, in C2 MCLs, this correlates with the acquisi-
tion of genetic changes and increased cell proliferation.
DISCUSSION
Recent reports using unbiased genome-wide approaches are
reshaping our perception of the role of DNA methylation in can-
cer (Agirre et al., 2015; Berman et al., 2012; Hansen et al., 2011;
Jones, 2012; Kulis et al., 2012; Ziller et al., 2013). Here, we have
analyzed the DNA methylome of MCL, a heterogeneous B cell
neoplasm, and decoded its clinicobiological impact in the
context of the DNA methylome of the entire B cell lineage. This
analytic strategy has allowed us to obtain insights into not only
the pathogenesis and clinical behavior of MCL but also the
general role of DNA methylation and its significance in cancer.
An important aspect of our study was the initial deconvolution
of the methylation estimates and in silico extraction of the
methylation levels of tumor cells. Thus, the results obtained
were not influenced by the composition of non-tumoral cells
within the MCL samples. We believe that this strategy can be
highly valuable for other epigenetic studies in which purified
tumor cells cannot be obtained.
Our results indicate a major link between the dynamic DNA
methylome during B cell maturation and MCL tumorigenesis
from various perspectives. From the biological point of view,
our findings put together two previous observations in
MCL. First, most MCLs are derived from antigen-experienced
B lymphocytes (Hadzidimitriou et al., 2011; Xochelli et al.,
2015), which is reflected by the fact that all MCLs in our study
have a DNA methylation profile more similar to antigen-experi-
enced cells. Second, MCLs with unmutated and mutated IGHV
may actually reflect a different cellular origin (Navarro et al.,
2012). In the case of unmutatedMCLs (C1), they retain an imprint
of B cells preceding the germinal center, and its cellular origin
may range from naive B cells lacking somatic hypermutation to
pro-germinal-center B cells with modest somatic hypermutation
(Kolar et al., 2007). In contrast, mutated MCLs (C2) clearly show
an imprint of B cells that have experienced the germinal-center
reaction. This phenomenon has also been observed in chronic
lymphocytic leukemia (CLL), in which three distinct clinicobiolog-
ical entities can be defined based on DNA methylation patterns
of B cell subpopulations at different maturation stages (Bhoi
et al., 2016; Kulis et al., 2012; Oakes et al., 2016; Queiros
et al., 2015). Overall, we propose an (epi)genetic model of MCL
pathogenesis (Figure 8G) in which C1 MCL cases derive from a
i.e., unmethylated regions in the C2 case that overlapwith H3K27ac peaks in the C2 case only (D), unmethylated regions in the C1 case that overlap with H3K27ac
peaks in the C1 case only (E), or with H3K27ac peaks in both the C1 and C2 case (F). In the lower part of these panels, the percentage of these respective DMRs
within the B cell-related, mixed, and B cell-independent DMRs is represented (***p < 0.001).
See also Figure S6, and Tables S4 and S5.
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Figure 7. Analysis of the Epigenetic and 3D Structure of the SOX11 Locus
(A) DMRs, ChIP-seq levels, and 4C-seq signals around the SOX11 locus. The represented region covers chr2:5,492,778-6,834,378 (hg19). Unmethylated DMRs
in the C1 (SOX11-positive) and C2 (SOX11-negative) MCL cases, respectively, are represented in the upper part of the panel by the blue and red arrows. In the
(legend continued on next page)
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range of germinal-center-inexperienced B cells that carry the
t(11;14) translocation and show absence or low levels of IGHV
somatic hypermutation (Navarro et al., 2012). Early during trans-
formation, these cells acquire genetic and epigenetic changes
and show expression of SOX11, which prevents these cells
from entering the germinal center (Palomero et al., 2015). C2
MCLs also carry the t(11;14) translocation but, in contrast to
cases from C1, they lack SOX11 expression and show high
levels of IGHV somatic hypermutation. This fits with the finding
that they seem to be derived from germinal-center-experienced
B cells, most likely memory B cells (Navarro et al., 2012). C2
MCLs with an indolent clinical course lack oncogenic mutations
and acquire few epigenetic changes, whereas C2 MCLs with a
more aggressive clinical behavior acquire mutations and present
extensive DNA methylation changes. The accumulation of DNA
methylation changes may suggest the presence of an epigenetic
drift derived from enhanced proliferation induced by oncogenic
mutations. However, this findingmay also point to a co-evolution
of genetic and epigenetic aberrations, as previously reported in
CLL (Oakes et al., 2014).
Like within the genetics field, amajor question in cancer epige-
nomics is how to detect potential drivers within a widespread
alteration of the DNA methylation landscape. Extrapolating
from recent cancer genomic studies, in which the number of po-
tential driver mutations is low compared with the entire muta-
tional burden (Puente et al., 2015; Schuster-Bockler and Lehner,
2012), the proportion of epigenetic drivers may also be low. This
is also supported by our data comparing chromatin states be-
tween normal B cells and primary cases, in which overall 56%
of the regions that undergo DNA methylation changes maintain
a stable chromatin environment, and therefore, the function of
these regions is most likely not altered. Furthermore, we showed
that the majority of CpGs with methylation changes in MCL are
affected in only one or few cases. Most likely, this low frequency
of recurrent patterns highlights the epigenetic heterogeneity
of cancer and reflects that DNA methylation changes globally
follow a stochastic model, as previously observed (Landan
et al., 2012; Landau et al., 2014; Shipony et al., 2014).
Despite the above-mentioned heterogeneity, an integrative
approach combining the DNA methylome and histone modifica-
tion patterns in primary MCL cases allowed us to identify DMRs
with potential functional impact. We propose that epigenetic
drivers should be searched in recurrent DMRs containing at
least some B cell-independent CpGs and showing a concurrent
change in the chromatin activation state. This approach is exem-
plified by our findings related to the SOX11 oncogene. With the
exception of activating histone marks in its promoter region
(Vegliante et al., 2011), no other epigenetic or genetic altera-
tions have been described to account for its de novo upre-
gulation in MCL. Here, we have identified a connection between
SOX11 expression and a cluster of hypomethylated DMRs
located 650 kb downstream of SOX11, a phenomenon that has
been observed previously for other cancer-related genes (Aran
and Hellman, 2013; Aran et al., 2013). This region showed the ca-
nonical elements of an enhancer element such as the presence
of nucleosomes containing H3K4me1 and H3K27ac. Further-
more, this region showed high interaction frequencies with the
SOX11 promoter at the 3D level exclusively in SOX11-express-
ing MCLs, strongly suggesting that it represents an important
SOX11 regulatory region in MCL.
From the clinical perspective, our results suggest that the
magnitude of DNA methylation changes is the most relevant in-
dependent prognostic factor in ourMCL series. However, amore
clinically oriented study with a better characterized and homoge-
neously treated series is required to validate our findings. The
extensive epigenetic changes observed in MCL suggest that
patients may benefit from the administration of epigenetic drugs
(Fiskus et al., 2012). However, the epigenetic heterogeneity
observed in MCL may influence efficacy, and it should be taken
into account as a potential means to stratify patients.
In conclusion, the analytic strategy presented in this study
highlights the significance of taking into account the dynamics
of the DNAmethylome during normal differentiation to better un-
derstand the cancer epigenome and its clinical implications.
Furthermore, our study underlines the importance of performing
an integrative whole-genome analysis, as proposed by interna-
tional consortia (Adams et al., 2012; Bernstein et al., 2010),
combining DNA methylation, histone modifications, 3D looping,
and gene expression to detect distant regulatory elements asso-
ciated with cancer.
EXPERIMENTAL PROCEDURES
The following experimental procedures represent a succinct summary of
the extensive materials and methods applied in the present study. Please refer
to the Supplemental Experimental Procedures for further details.
Samples Studied
A total of 82 MCL samples, 4 MCL cell lines (Z-138, JVM-2, JEKO-1, and
Granta-519) and 67 samples fromB cell subpopulations at different maturation
stages (Kulis et al., 2015) were used in the present study. Clinical and biological
features of the MCL patients are shown in Table S1. Patients gave their written
informed consent, and the study was approved by the clinical research ethics
committee of the Hospital Clinic of Barcelona (number 2009/5069) and the in-
ternal review board of the University of Kiel (number 447/10).
Deconvolution of DNA Methylation Values
We estimated the proportion of B cells, CD8+ T cells, CD4+ T cells, natural killer
cells, monocytes, and granulocytes in the MCL samples (algorithm adapted
from Houseman et al., 2012; Jaffe and Irizarry, 2014), and purified the
lower two panels, normalized ChIP-seq intensities for H3K4me3, H3K4me1, and H3K27ac are depicted for the C1 and C2 MCL case. Furthermore, normalized
4C-seq intensities are indicated using the enhancer in MCL C1 (chr2:6,465,559-6,496,708, hg19) or the SOX11 region as viewpoint. tel, telomere; cen,
centromere.
(B) Normalized 4C-seq intensities taking the SOX11 region as viewpoint in three SOX11-positive MCL cell lines (Z-138, JEKO-1, GRANTA-519), one SOX11-
negative MCL cell line (JVM-2), and in normal naive and memory B cells (naiBCs and memBCs).
(C) Mean methylation levels of four CpGs within the SOX11-positive MCL enhancer region in naive B cells (green, n = 4), SOX11-negative (blue, n = 10), and
SOX11-positive (orange, n = 12) MCLs as analyzed by bisulfite pyrosequencing. Data show means ± SD. *p < 0.01, **p < 0.001, ***p < 0.0001 (Wilcoxon test for
independent samples).
(D) Model of the SOX11 locus in SOX11-negative MCL (upper) and SOX11-positive MCL (lower).
See also Table S6.
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Figure 8. Link between the Number of DNA Methylation Changes and Prognosis
(A) Relationship between the number of epigenetic changes and overall survival through a linear predictor. Red line, perfect linear relationship; black line,
observed regression line; dashed line, 95% confidence interval of observed regression.
(B) Kaplan-Meier plots of MCLs with lower versus higher number of differentially methylated CpGs compared with HPCs in C1 and C2 MCLs.
(legend continued on next page)
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methylation values of the B cell (i.e., tumor) fraction by subtracting the methyl-
ation estimates of the non-B cell fractions.
Epigenomic Analyses
We applied a range of different epigenomic methods, including the
HumanMethylation BeadChip (Illumina) in 82 primary MCLs and 67 normal
B cell subpopulations (Kulis et al., 2015); WGBS in twoMCLs; bisulfite pyrose-
quencing in 22 MCL cases and naive B cells; ChIP-seq with six different his-
tone modifications in the two MCLs analyzed by WGBS as well as naive and
memory B cells, and finally 4C-seq in the two MCLs analyzed by WGBS,
four MCL cell lines as well as naive and memory B cells.
Statistical Analysis
The relationships between MCL subgroups and clinical and biological
variables of patients was evaluated using Fisher’s exact test or t tests, and
statistical significance was defined as p < 0.05 (corrected for multiple testing
if necessary). Univariate and multivariate survival analyses were used to
measure the impact of DNA methylation changes in the clinical behavior of
MCL patients. All analyses were performed with IBM-SPSS Statistics version
20 or various packages within the R software.
ACCESSION NUMBERS
WGBS, ChIP-seq, and microarray data have been deposited in the
European Genome-phenome Archive (EGA) under accession numbers
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